Clinical trial · Observational
Evaluation of Diet and Exercise in Prostate Cancer Patients
Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed With Lupron (CRONOS II)
NCT01960881CI-TRIAL-00060214CRONOS IIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with Lupron.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Prostate Cancer Patients
- description
- Prostate Cancer Patients
Primary outcomes (3)
- measure
- Changes in the patient quality of life (QoL) using the Medical Outcomes Study Short Form - 36 (SF-36)
- timeFrame
- From Month 0 to Month 18
- description
- The SF-36 Health is a 36-item general health self-administered questionnaire consisting of 8 scales measuring Physical Function, Physical Role limitations, Vitality, General Health, Pain, Social Function, Emotional Role limitations, and Mental Health.
- measure
- Change in exercise duration
- timeFrame
- From Month 0 to Month 18
- description
- Assessed at every visit what was the amount of various types of exercise performed in the previous month.
- measure
- Change in dietary habits
Eligibility
Eligibility (as posted)
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: i. Adult ≥ 18 years old ii. Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel. iii. Diagnosed with PCa. iv. Prescribed Lupron as part of his treatment by his treating physician. Exclusion Criteria: i. Patient cannot or will not sign informed consent. ii. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of PCa. iii. More than 6 months of therapy if currently on continuous Luteinizing hormone-releasing hormone (LHRH) treatment. iv. If at study enrollment the intent is to only prescribe 1 dose of Lupron (leuprolide acetate)
References
Publications (0)
Data not yet available
No reference posted for this study.